e-learning
resources
Berlin 2008
Monday, 06.10.2008
Treatment and outcome in hospitalised patients with community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma fibrinogen concentration is an independent marker of severity in patients with community acquired pneumonia
J. Chalmers, A. Singanayagam, M. Murray, A. Hill (Edinburgh, United Kingdom)
Source:
Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Session:
Treatment and outcome in hospitalised patients with community-acquired pneumonia
Session type:
E-Communication Session
Number:
1850
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Chalmers, A. Singanayagam, M. Murray, A. Hill (Edinburgh, United Kingdom). Plasma fibrinogen concentration is an independent marker of severity in patients with community acquired pneumonia. Eur Respir J 2008; 32: Suppl. 52, 1850
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
D-dimer is an independent marker predicting severity in community acquired pneumonia
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Elevated creatinine is a sensitive severity marker in community acquired pneumonia
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008
Measurement of serum total antioxidant status in patients with community acquired pneumonia: correlation with the severity of the disease
Source: Eur Respir J 2002; 20: Suppl. 38, 283s
Year: 2002
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Serum levels of soluble forms of intracellular adhesion molecules in patients with community acquired pneumonia
Source: Annual Congress 2008 - Airway infection and host defence
Year: 2008
Total antioxidant capacity and C-reactive protein levels in patients with community acquired pneumonia
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Influence of older age on biomarker concentrations in patients with community acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005
Plasma levels of LL37 in patients with and at risk of acute lung injury
Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury
Year: 2011
Admission serum glucose levels are a risk factor predicting short- and long-term mortality in community acquired pneumonia
Source: Annual Congress 2012 - Hot topics in respiratory infections
Year: 2012
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
Elevated plasma EPCR levels early post ICU admission predict sepsis development
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
Thromboprophylaxis and the relationship between C-reactive protein and plasma fibrinogen in patients with acute exacerbations of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 555s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept